GlassScriptPhysician profile
Kimala Aleisha Harris
NPI 1386137677
$12,658.89
in general payments reported to CMS, 2019-2025
59 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $1,437 · 2021: $2,279 · 2022: $1,881 · 2023: $2,550 · 2024: $2,068 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,505 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,504.63 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,725.55 | 2020-2025 | |
| Pfizer INC. | $1,278.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,265.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,144.93 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,074.01 | 2020-2025 | Mounjaro, Zepbound |
| Stryker Corporation | $754.91 | 2021-2024 | Variax, Anchorage, Vitoss |
| Optinose US, INC. | $391.91 | 2020-2023 | |
| Astellas Pharma US INC | $360.69 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $300.01 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $292.88 | 2020-2022 | |
| Amgen INC. | $246.72 | 2022-2025 | Evenity, Repatha, Repatha |
| Eisai INC. | $245.42 | 2020-2022 | |
| Glaxosmithkline, LLC. | $240.34 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Corium, LLC | $236.99 | 2022-2025 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $199.38 | 2020-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimala Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.